Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-08-29
1999-11-02
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514318, 546193, 546257, A61K 3144, C07D21168
Patent
active
059771445
ABSTRACT:
This invention relates to compositions for benzylidene- and cinnamylidene-anabaseines and methods for using these compositions for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors. These compositions target the alpha7 receptor subtype with little or no activation of the alpha4beta2 or other receptor subtypes.
REFERENCES:
patent: 3247213 (1966-04-01), Buchel et al.
patent: 3265573 (1966-08-01), Goldberg
patent: 3275625 (1966-09-01), Muller et al.
patent: 3426130 (1969-02-01), Riffkin et al.
patent: 4155909 (1979-05-01), Sanders et al.
patent: 4195645 (1980-04-01), Bradley et al.
patent: 4728605 (1988-03-01), Fudenberg et al.
patent: 4965074 (1990-10-01), Leeson et al.
patent: 5015570 (1991-05-01), Scangos et al.
patent: 5187169 (1993-02-01), Lippiello et al.
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5214060 (1993-05-01), Caldwell et al.
patent: 5227385 (1993-07-01), Caldwell et al.
patent: 5227391 (1993-07-01), Caldwell et al.
patent: 5232932 (1993-08-01), Caldwell et al.
patent: 5232933 (1993-08-01), Lippiello et al.
patent: 5242916 (1993-09-01), Lippiello et al.
patent: 5242934 (1993-09-01), Lippiello et al.
patent: 5242935 (1993-09-01), Lippiello et al.
patent: 5248690 (1993-09-01), Caldwell et al.
patent: 5276043 (1994-01-01), Lippiello et al.
patent: 5516785 (1996-05-01), Zoltewicz et al.
patent: 5602257 (1997-02-01), Zoltewicz et al.
patent: 5741802 (1998-04-01), Kem et al.
Arendash et al., "Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21," Brain Research, 674:252-259, 1995.
Arendash et al., "Nicotine enhances the learning and memory of aged rats," Pharm. Biochem. Behavior, 52(3):517-523, 1995.
Arneric et al., "Neuronal nicotinic acetylcholine receptor (nAChR) diversity and therapeutic potential of selective ligands," In: Book of Abstracts, Issue Pt. 2, (210th ACS National Meeting, American Chemical Society, Washington, D.C., Neuroscience Research, Abbott Laboratories, Abbott Park, IL, Aug. 20-24, 1995.
Baron, "Cigarette smoking and Parkinson's disease," Neurology, 36:1490-1496, 1986.
Briggs et al., "Ganglionic nicotinic acetylcholine receptor activation by the novel agonist ABT-418," Drug Dev. Res., 34:39-46, 1995.
Briggs et al., "Human .alpha.7 nicotinic acetylcholine receptor responses to novel ligands," Neuropharmacology, 34(6):583-590, 1995.
Castonguay and Hecht, "Synthesis of carbon-14 labeled 4-(methylnitrosamino)-1-(3-pyridyl)-1-butonone," J. Labelled Compounds Radiopharmaceuticals, 22(1):23-28, 1984.
Clarke et al., "Electrophysiological actions of nicotine on substantia nigra single units," Br. Pharmac., 85:827-835, 1985.
Fujisawa et al., "Extension of Bichler Napieralski reaction," Chemical Abstracts, 54(8)185-188, 1960.
Gallulo et al., "Cyclization of .omega.-halonitriles with organolithiums," Chemical Abstracts, 113(1):593, Abstract 6111k, 1990.
Gallulo et al., "Cyclization of .omega.-halonitriles with organolithiums," Organic Preparations and Procedures Int., 21(3):297-301, 1989.
Giacobini, "Cholinergic receptors in human brain: effects of aging and alzheimer disease," Neuros. Res., 27:548-560, 1990.
Grant (Ed.), In: Hackh's Chemical Dictionary, McGraw-Hill Book Co., New York, p. 642, 1983.
Hamlet and Durst, "1-(Dialkylaminomethyl)-azetidin-2-ones. Intermediates in a highly stereoselective preparation of trans-3,4-disubstituted azetidin-2-ones," Canadian J. Chem., 61(2):411-415, 1983.
Hodges, "Nicotine as a tool to characterize the role of the forebrain cholinergic projection system in cognition," Biol. of Nicotine: Current Res. Issue, Lippiello et al. (eds), Raven Press, Ltd., NY 1992.
Hu et al., "Chemical studies on tobacco smoke XXIII. Synthesis of carbon-14 labelled myosmine, nirnicotine and N'-nitrosonornicotine," Journal of Labelled Compounds, 10(1):79-89, 1973.
Hunter et al., "A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus," Neuroscience Ltrs., 168:130-134, 1994.
International Search Report dated Nov. 12, 1993.
Jones, "Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease," Psychopharm., 108:485-494, 1992.
Kellar and Wonnacott, "Nicotinic cholinergic receptors in Alzheimer's disease," In: Nicotine Psychopharmacology, pp. 343-373, 1992.
Kem and Papke, "Actions of anabaseine and DMAB-anabaseine upon neuronal .alpha..sub.4 .beta..sub.2 and PC12 cell nicotinic receptors," Soc. Neuroscience, 18(2)569.19, 1992.
Kem, "A study of the occurrence of anabaseine in paranemertes and other nemertines," Toxicon, 9:23-32, 1971a.
Kem, "Biochemistry of Nemertine Toxins," Marine Pharmacognosy, Chapter II, 37:84, 1973.
Kem et al., "Hoplonemertine Worms--a New Source of Pyridine Neurotoxins," Experientia, 684-686, 1976.
Kem et al., "Isolation and structure of a hoplonemertine toxin," Toxicon, 9:15-22, 1971b.
Kem, "Occurance of anabaseine in paranemertes and other nemertines," Toxicon, 9(1):23-32, 1971. (Abstract only).
Kem, "Pyridine alkaloid distribution in the hoplonemetines," Hydrobiologia, 156:145-151, 1988.
Kem, "Structure and Action of Nemertine Toxins, " American Zoology, 25:99-111, 1985.
Kem, "Worm Toxins," Handbook of Natural Toxins, Marcei Dekker Inc., N.Y., 3:353-360, 1988.
Leete, "Aberrant Biosynthesis of 5-Fluoroanabasine from 5-Fluoro[5,6-.sup.14 C,.sup.13 C.sub.2 ]nicotinic Acid, Established by Means of Carbon-13 Nuclear Magnetic Resonance," The Journal of Organic Chemistry, 44(2):165-168, 1979.
Leete and Chedekel, "The Aberrant Formation of (-)-N-Methylanabasine From N-Methyl-Piperideinium Chloride in Nicotiana Tabacum and N. Glauca," Phytochemistry, 11:2751-2756, 1972.
Martin, "Cytoprotective actions of 2,4-dimethoxybenzylidene anabaseine in differentiated PC12 cells and septal cholinergic neurons," Drug Dev. Res., 31:135-141, 1994.
Marttila and Rinne, "Progression and survival in Parkinson's disease," Acta Neurol. Scand., 84(136):24-28, 1991.
McGehee et al., "Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors," Science, 269:1692-1695, 1995.
Meyer et al., "Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors," Drug Dev. Res., 31:127-134, 1994.
Meyer et al., "Effects of nucleus basalis lesions on the muscarinic and nicotinic modulation of [.sup.3 H] acetylcholine release in the rate cerebral cortex," Neurochem., 49:1758-1762, 1987.
Nanri et al., "GTS-21, a nicotinic agonist, protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats," Jpn. J. Pharmacol., 74(3):285-289, 1997.
Nanri et al., "Protective effect of GTS-21, a novel nicotinic receptor agonist, on neuronal cell death," Jpn. J. Pharmacol., 71(Supp.1):171, 1996.
Newhouse et al., "The effects of nicotinic agents on human cognition: possible therapeutic applications in Alzheimer's and Parkinson's diseases," Med. Chem. Res., 2:628-642, 1993.
Nomura et al., "The reaction of 5-benzylidine-2,3,4,5-tetrahyteropyridine with some nucleophiles," Bull Chem. Society of Japan, 57:1271, 1984.
Papke and Heinemann, "Partial agonist properties of cytosine on neuronal nicotinic receptors containing the .beta.2 subunit," Molecular Pharmacology, 45:142-149, 1993.
Papke, "The kinetic properties of neuronal nicotinic receptors: genetic basis of functional diversity," Progress in Neurobiology, 41:509-531, 1993.
Parcell et al., The preparation of tetrahydro pyridines from Enamies and Imines, J. of Organic Chemistry, 28:3469, 1963.
Pathak et al., "Synthesis of [4-.sup.2 H.sub.2 ]-, (4R)[4-.sup.2 H.sub.1 ]-and (4S)[4-.sup.2 H.sub.1 ]-4-(methylnitrosamino)-1-(3'-pyridyl)-1-butanone, C-4 deuteriated isotopomers of the procarcinogen NNK," Tetrahedron, 46(5):1733-1744, 1990.
Patneau et al., "Hippocampal Neurons Exhibit Cyclothiazide-sensitive Rapidly Desensitizing Responses to Kainate," The Journal of Neuroscience, 13(8):3496-3509, 1993.
Rinne et al., "A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease," Brain R
Day Arthur
De Fiebre Christopher M.
Kem William
Meyer Edwin
Papke Roger
Criares Theodore J.
University of Florida
LandOfFree
Methods of use and compositions for benzylidene- and cinnamylide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of use and compositions for benzylidene- and cinnamylide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of use and compositions for benzylidene- and cinnamylide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2135908